Autopsy report · NCT01747993

Tamsulosin for Urinary Retention in Hospitalized Older Women

“low inclusion”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 5 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Urinary Retention

Interventions

Tamsulosin (0.4 mg/j); Placebo

Participants

34

Sites

1

Countries

France

Trials that died the same way

• Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
  “low of inclusions” (95% match in meaning)
• The Dutch Asymptomatic Mitral Regurgitation Trial
  “low inclusion rate” (77% match in meaning)
• Pronostic Value of Endothelial Dysfunction in Heart Failure
  “Not enough inclusions” (76% match in meaning)
• Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging
  “low inclusion rates” (76% match in meaning)
• Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.
  “insufficient inclusions” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.